TABLE 1.

The primers design.

Gene	Forward	Reverse
Nr1d1	AGAGAGGCCATCACAACCTC	TGTAGGTGATAACACCACCTGT
Prkaa1	CCAGGTCATCAGTACACCATCT	TTTCCTTTTCGTCCAACCTTCC
Ppargc1a	GAGTTGAAAAAGCTTGACTGGC	CAGCACACTCTATGTCACTCC
Mtor	CCACGTGGTTAGCCAGACT	TAGCGGATATCAGGGTCAGGA
Fbxo32	CAAAGGAAGTACGAAGGAGCG	TCAGCTCCAACAGCCTTACTA
Murf1	CAGGCTGCGAATCCCTACTG	GCCGGTCCATGATCACTTCA
Ubc	CGCGCTGATCCCTCCG	CTGCATCGTCTCTCTCACGG
Bcat2	TATGGACCCACTGTGGCTGT	CAGCTCCAGTACTCCGTCTTC
Gapdh	AAGAGGGATGCTGCCCTTAC	CGGGACGAGGAAACACTCTC

Nr1d1, Nuclear receptor subfamily 1, group D, member 1; Prkaa1, Protein kinase, AMP-activated, alpha 1 catalytic subunit; Ppargc1a, Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha; Mtor, Mechanistic target of rapamycin kinase; Fbxo32, F-box protein 32; Trim63, Tripartite motif-containing 63; Ubc, Ubiquitin C; Bcat2, Branched-chain aminotransferase 2, mitochondrial; Gapdh, Glyceraldehyde-3-phosphate dehydrogenase.